BIOTECH ASSISTANT / FIELD NOTES

Review identifies higher patient exposure for some drugs in chronic inflammation

Academic source · Clinical Pharmacology & Therapeutics / PMC

Source published: 2026-10-29 · Event / reporting date: 2026-10-29

Site published: 2026-11-05 · Updated: 2026-11-05

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What the paper reports

Based on the article abstract, a review of 20 approved small-molecule medicines for selected chronic inflammatory diseases found more than 25% higher exposure in patients for five medicines, using reported population pharmacokinetic analyses. The authors highlight CYP3A4 and CYP2C19 metabolism. This cross-drug review supports risk assessment, not automatic dose changes for individual patients.

Why this paper is included

Analysis: Dose translation from healthy volunteers may need disease-state assessment; population-model evidence should inform study design rather than stand-alone prescribing decisions.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Clinical Pharmacology & Model-Informed Development

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

Pharmaron Quotient Sciences Crystal Bio Solutions Frontage Laboratories Altasciences

Explore field companies →Explore literature →

Related updates

2026-11-06European Journal of Drug Metabolism and Pharmacokinetics

Progesterone PopPK study combines machine-learning screening with conventional covariate modeling

A study in European Journal of Drug Metabolism and Pharmacokinetics modeled subcutaneous aqueous progesterone using single-dose crossover data from 50 healthy Chinese postmenopausal women. Machine-learning approaches screened potential covariates before conventional PopPK evaluation. Height and body-weight effects remained statistically identifiable but had limited clinical significance. Simulated repeated-dose exposure is model-derived, rather than an observed efficacy outcome in fertility patients.

Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-05PharmaIN Corporation

PharmaIN reports Phase 1 multiple-dose PHIN-214 findings in cirrhosis

On November 5, PharmaIN reported conference findings from PHIN-001: 12 participants with Child-Pugh B cirrhosis received PHIN-214; 10 completed 28 days. The issuer described Grade 1–2 treatment-related adverse events and exploratory renal, hemodynamic and PK findings. The ongoing small Phase 1 study does not establish clinical benefit. This is a company conference announcement, not a peer-reviewed paper.

Clinical Pharmacology & Model-Informed Development Ask AI ↗

2026-11-05Ethris / GlobeNewswire

Ethris reports exploratory antiviral and exposure-response signals for nasal ETH47 in asthma

Ethris reported topline results from a randomized Phase 2a rhinovirus-challenge study involving 50 adults with asthma. A single nasal dose of ETH47, an interferon-lambda-encoding mRNA candidate, produced local expression and lower day-two viral load. Symptom improvements were described as numerical trends; exposure-response subgroup findings remain exploratory, without established clinical efficacy.

Companies mentionedEthris ↗

mRNA / LNP Clinical Pharmacology & Model-Informed Development Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗